Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
Koji Abe, Masashi Aoki, Shoji Tsuji, et al.
The Lancet Neurology (2017) Vol. 16, Iss. 7, pp. 505-512
Closed Access | Times Cited: 804

Showing 26-50 of 804 citing articles:

Amyotrophic lateral sclerosis: translating genetic discoveries into therapies
Fulya Akçimen, Elia R. Lopez, John E. Landers, et al.
Nature Reviews Genetics (2023) Vol. 24, Iss. 9, pp. 642-658
Open Access | Times Cited: 115
WNT-β Catenin Signaling as a Potential Therapeutic Target for Neurodegenerative Diseases: Current Status and Future Perspective
Kakarla Ramakrishna, Lakshmi Vineela Nalla, Naresh Dumala, et al.
Diseases (2023) Vol. 11, Iss. 3, pp. 89-89
Open Access | Times Cited: 105
Liquid-Liquid Phase Separation of TDP-43 and FUS in Physiology and Pathology of Neurodegenerative Diseases
Jenny L. Carey, Lin Guo
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 102
Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics – An AI-Enabled Biological Target Discovery Platform
Frank W. Pun, Bonnie Hei Man Liu, Xi Long, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 74
Current State and Future Directions in the Therapy of ALS
Laura Tzeplaeff, Sibylle Wilfling, Maria Viktoria Requardt, et al.
Cells (2023) Vol. 12, Iss. 11, pp. 1523-1523
Open Access | Times Cited: 59
Effects of tofersen treatment in patients with SOD1-ALS in a “real-world” setting – a 12-month multicenter cohort study from the German early access program
Maximilian Wiesenfarth, Johannes Dorst, Dávid Brenner, et al.
EClinicalMedicine (2024) Vol. 69, pp. 102495-102495
Open Access | Times Cited: 47
European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERNEURO‐NMD)
Philip Van Damme, Ammar Al‐Chalabi, Peter M. Andersen, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 6
Open Access | Times Cited: 40
Update on Antioxidant Therapy with Edaravone: Expanding Applications in Neurodegenerative Diseases
Toru Yamashita, Koji Abe
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2945-2945
Open Access | Times Cited: 23
Mitochondrial Permeability Transition, Cell Death and Neurodegeneration
Artyom Y. Baev, Andrey Y. Vinokurov, Elena Potapova, et al.
Cells (2024) Vol. 13, Iss. 7, pp. 648-648
Open Access | Times Cited: 18
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders
Jeffrey L. Cummings, Charlotte E. Teunissen, Brian Fiske, et al.
Nature Reviews Drug Discovery (2025)
Closed Access | Times Cited: 3
Advancements in genetic research and RNA therapy strategies for amyotrophic lateral sclerosis (ALS): current progress and future prospects
Paola Ruffo, Bryan J. Traynor, F. L. Conforti
Journal of Neurology (2025) Vol. 272, Iss. 3
Open Access | Times Cited: 2
Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis
Amit U. Joshi, Nay L. Saw, Hannes Vogel, et al.
EMBO Molecular Medicine (2018) Vol. 10, Iss. 3
Open Access | Times Cited: 160
Mitochondrial Permeability Transition: A Molecular Lesion with Multiple Drug Targets
Thomas Briston, David L. Selwood, György Szabadkai, et al.
Trends in Pharmacological Sciences (2018) Vol. 40, Iss. 1, pp. 50-70
Open Access | Times Cited: 157
Are Astrocytes the Predominant Cell Type for Activation of Nrf2 in Aging and Neurodegeneration?
Jeffrey R. Liddell
Antioxidants (2017) Vol. 6, Iss. 3, pp. 65-65
Open Access | Times Cited: 154
Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention
Teresa Cunha‐Oliveira, Liliana Montezinho, Catarina Mendes, et al.
Oxidative Medicine and Cellular Longevity (2020) Vol. 2020, pp. 1-29
Open Access | Times Cited: 137
Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials
Leonard H. van den Berg, Eric J. Sorenson, Gary Gronseth, et al.
Neurology (2019) Vol. 92, Iss. 14
Open Access | Times Cited: 124
Traumatic Brain Injury: Oxidative Stress and Novel Anti-Oxidants Such as Mitoquinone and Edaravone
Helen Ismail, Zaynab Shakkour, Maha Tabet, et al.
Antioxidants (2020) Vol. 9, Iss. 10, pp. 943-943
Open Access | Times Cited: 120
Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities
Juan I. Sbodio, Solomon H. Snyder, Bindu D. Paul
Antioxidants and Redox Signaling (2018) Vol. 30, Iss. 11, pp. 1450-1499
Open Access | Times Cited: 114
Results from Phase I Clinical Trial with Intraspinal Injection of Neural Stem Cells in Amyotrophic Lateral Sclerosis: A Long-Term Outcome
Letizia Mazzini, Maurizio Gelati, Daniela Celeste Profico, et al.
Stem Cells Translational Medicine (2019) Vol. 8, Iss. 9, pp. 887-897
Open Access | Times Cited: 104
On the Clinical Pharmacology of Reactive Oxygen Species
Ana I. Casas, Cristian Nogales, Hermann AM Mucke, et al.
Pharmacological Reviews (2020) Vol. 72, Iss. 4, pp. 801-828
Open Access | Times Cited: 100
Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis
Leeanne McGurk, Jelena Mojsilovic‐Petrovic, Vivianna M. Van Deerlin, et al.
Acta Neuropathologica Communications (2018) Vol. 6, Iss. 1
Open Access | Times Cited: 99
Disease-modifying therapies in amyotrophic lateral sclerosis
Adriano Chiò, Letizia Mazzini, Gabriele Mora
Neuropharmacology (2020) Vol. 167, pp. 107986-107986
Closed Access | Times Cited: 98
Isogenic FUS-eGFP iPSC Reporter Lines Enable Quantification of FUS Stress Granule Pathology that Is Rescued by Drugs Inducing Autophagy
Lara Marrone, Ina Poser, Ian Casci, et al.
Stem Cell Reports (2018) Vol. 10, Iss. 2, pp. 375-389
Open Access | Times Cited: 97
Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis
Johannes Dorst, Albert C. Ludolph, Annemarie Huebers
Therapeutic Advances in Neurological Disorders (2017) Vol. 11
Open Access | Times Cited: 95
Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis
Mengmeng Jin, René Günther, Katja Akgün, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 93

Scroll to top